The treatment of HF is usually dominated by chemical drugs, which evolve from the traditional ‘cardiotonic, diuretic, vasodilator’ to the golden triangle combination therapy including the basis of aldosterone receptor antagonist (also known as mineralocorticoid receptor antagonist, MRA), angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), and β receptor blocker [18,19]. Here, NR3C2 is linked to hydrops fetalis.